Technical Analysis for SNDX - Syndax Pharmaceuticals, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
10.75 | 3.07% | 0.32 |
SNDX closed up 3.57 percent on Wednesday, February 19, 2020, on 1.35 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Mar 5
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Historical SNDX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New Uptrend | Bullish | 3.07% | |
| Stochastic Reached Overbought | Strength | 3.07% | |
| Wide Bands | Range Expansion | 3.07% | |
| Gapped Up | Strength | 3.07% | |
| Overbought Stochastic | Strength | 3.07% | |
| Pocket Pivot | Bullish Swing Setup | 6.75% | |
| Volume Surge | Other | 6.75% | |
| Multiple of Ten Bullish | Other | 6.75% | |
| Wide Bands | Range Expansion | 6.75% | |
| Doji - Bearish? | Reversal | 12.33% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 03/05/2020
- Sector: Healthcare
- Industry: Biotechnology
Syndax Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics in oncology. The company's lead product candidate is entinostat, an epigenetic therapy for treatment-resistant cancers, such as breast cancer and lung cancer, as well as other indications comprising solid tumors and hematological malignancies. Its Entinostat is an oral histone deacetylase inhibitor that targets cancer cell growth and resistance pathways that limit the effectiveness and durability of cancer therapies. The company has a collaborative research and development agreement with the National Cancer Institute; and Genentech. Syndax Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Waltham, Massachusetts.
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Cancer Therapies Pyridines Lung Cancer Late Stage Biopharmaceutical Hematological Malignancies Benzamides Carbamates Draft:Syndax National Cancer Institute
Medicine Chemistry Cancer Clinical Medicine Solid Tumors Breast Cancer Antineoplastic Drugs Cancer Therapies Pyridines Lung Cancer Late Stage Biopharmaceutical Hematological Malignancies Benzamides Carbamates Draft:Syndax National Cancer Institute
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.11 |
| 52 Week Low | 4.52 |
| Average Volume | 158,095 |
| 200-Day Moving Average | 8.25 |
| 50-Day Moving Average | 8.75 |
| 20-Day Moving Average | 8.83 |
| 10-Day Moving Average | 9.73 |
| Average True Range | 0.69 |
| ADX | 25.41 |
| +DI | 32.29 |
| -DI | 13.75 |
| Chandelier Exit (Long, 3 ATRs ) | 8.84 |
| Chandelier Exit (Short, 3 ATRs ) | 8.39 |
| Upper Bollinger Band | 11.49 |
| Lower Bollinger Band | 6.16 |
| Percent B (%b) | 0.8 |
| BandWidth | 60.39 |
| MACD Line | 0.45 |
| MACD Signal Line | 0.33 |
| MACD Histogram | 0.1259 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 11.38 | ||||
| Resistance 3 (R3) | 11.39 | 11.08 | 11.22 | ||
| Resistance 2 (R2) | 11.08 | 10.84 | 11.08 | 11.16 | |
| Resistance 1 (R1) | 10.76 | 10.69 | 10.92 | 10.75 | 11.11 |
| Pivot Point | 10.45 | 10.45 | 10.54 | 10.45 | 10.45 |
| Support 1 (S1) | 10.13 | 10.21 | 10.29 | 10.12 | 9.75 |
| Support 2 (S2) | 9.82 | 10.06 | 9.82 | 9.70 | |
| Support 3 (S3) | 9.50 | 9.82 | 9.64 | ||
| Support 4 (S4) | 9.49 |
